Introduction: The aim was to clarify the influence on patient prognosis of ground glass opacity (GGO) component in each new TNM stage and propose grouping reflecting the prognosis more accurately. Methods: We examined the data on 1290 patients who underwent lung cancer resection from 2003 to 2011. The demographics and overall survival of patients with adenocarcinoma with and without GGO, squamous cell carcinoma, and the others were compared according to clinical stage from 0 to IB. In adenocarcinoma, we examined the distribution of histological subtypes of adenocarcinoma with and without GGO in each clinical stage. Results: Each clinical stage differentiated overall survival well. However, the prognosis of the patients with adenocarcinoma with GGO was considerably more favorable than that of the others in clinical stage IA2 and IA3 but not of those in clinical stage IB. In clinical stage 0 to IA3, patients showing adenocarcinoma in situ, minimally invasive adenocarcinoma, and invasive lepidic predominant adenocarcinoma accounted for about 50% of the total number of patients with adenocarcinoma with GGO (stage 0, 16 of 21; stage IA1, 113 of 143; stage IA2, 80 of 157; and stage IA3, 45 of 94). In clinical stage IB, 20% of adenocarcinomas with GGO showed invasive solid predominant adenocarcinoma (IB, seven of 38). Most of the adenocarcinomas without GGO were in clinical stage IA2 to IB, and the distribution of histological subtypes was similar at each clinical stage. Invasive acinar and solid predominant adenocarcinomas were more common in adenocarcinoma without GGO. Conclusions: Clinical T classification considering GGO component may offer more accurate prognosis for patients with lung cancer less than 3 cm in invasive diameter.

中文翻译：

---

临床I期非小细胞肺癌患者磨玻璃不透明度和相应病理结果对生存的影响

介绍：旨在阐明每个新TNM分期毛玻璃样混浊（GGO）成分对患者预后的影响，并提出更准确反映预后的分组。方法：我们检查了 2003 年至 2011 年接受肺癌切除术的 1290 例患者的数据。根据临床分期从 0 到 IB 比较了伴和不伴 GGO、鳞状细胞癌和其他腺癌患者的人口统计学和总生存期。 . 在腺癌中，我们检查了在每个临床阶段有和没有 GGO 的腺癌组织学亚型的分布。结果：每个临床分期都能很好地区分总生存期。然而，GGO腺癌患者的预后明显优于临床IA2和IA3期的其他患者，但临床IB期的患者则不然。在临床 0 至 IA3 期，显示原位腺癌、微浸润腺癌和浸润性贴壁腺癌的患者约占 GGO 腺癌患者总数的 50%（0 期，21 人中的 16 人；IA1 期，113 人为143；IA2 阶段，157 中的 80；和 IA3 阶段，94 中的 45）。在临床分期 IB 中，20% 的 GGO 腺癌表现为侵袭性实性腺癌（IB，38 个中有 7 个）。大多数无 GGO 的腺癌临床分期为 IA2 至 IB，各临床分期组织学亚型分布相似。在没有 GGO 的腺癌中，浸润性腺泡和实性占优势的腺癌更常见。结论：考虑到 GGO 成分的临床 T 分类可以为浸润直径小于 3 cm 的肺癌患者提供更准确的预后。